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Abstract Cytokines act as pleiotropic polypeptides able to regulate inflammatory/
immune responses and to provide important signals in physiological and patho-
logical processes. Several cytokines (Th1, Th2, and Th17) seem to be involved in
the pathophysiology of Behc¸et’s disease, a chronic immune-mediated disease
characterized by oral and genital lesions and ocular inflammation. Its individual
susceptibility seems to be modulated by genetic variants in genes codifying these
cytokines. Th1 and Th17 seem to be involved in the disease’s active phases, and
Th2 seems to affect the development or severity of the disease; however, contrasting
data are reported. In this study, some genetic variants of the Th1/Th2 cytokine genes
were investigated in Sicilian patients and age- and gender-matched controls. Three
very significant associations with Behc¸et’s disease were detected, and combined
genotypes associated with increased disease risk were identified. Results obtained
point to the key role of Th1/Th2 cytokine genetic variants in disease susceptibility.
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Introduction
Currently, data that demonstrate the fundamental impact of genetics in human
autoimmune diseases are rapidly accumulating. In particular, genetic variants of
multiple inflammatory/immune genes may play roles as risk or predisposing factors.
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This also confirms the involvement of different inflammatory/immune pathways in
the complex pathophysiology of these diseases. In this scenario, the Th1 and Th2
cytokines and their receptors seem to be crucial (Gregersen and Olsson 2009; Cho
and Gregersen 2011).
The Th1 (i.e., IL-12, IL-18) and Th2 (IL-4, IL-13, IL-10) cytokines, involved in
host protection from pathogen invasions and maintenance of immune balance, are
finely tuned, and their imbalance seems to be the cause of various immune
disorders, including autoimmune diseases such as Behc¸et’s disease (Zygmunt and
Veldhoen 2011; Bluestone et al. 2009; Kuchroo et al. 2012). Emerging evidence is
also demonstrating the promotion of Th17 responses and the suppression of T
regulatory cells (Tregs) in the pathophysiology of these diseases (Hamzaoui et al.
2011, 2012; Pineton de Chambrun et al. 2012; Zhou et al. 2012).
Behc¸et’s disease is a systemic vasculitis characterized by oral and genital lesions
and ocular inflammation. Its pathogenesis is unknown; however, an increased and
deregulated immune response triggered by pathogenic agents characterizes its
pathophysiology (Kapsimali et al. 2010). An increased infiltration of both T cells
and innate immune cells into the affected organs and tissues has been identified. In
particular, excessive Nucleotide-binding oligomerization domain-containing 2
(NOD2) and Toll-like receptor (TLR) expression, responsible for the induction of
pro-inflammatory cytokines and Th1 response, has been observed in cells from
broncho-alveolar lavage of Behc¸et’s patients with pulmonary manifestations
(Hamzaoui et al. 2012). Expansion of Th17 and Th1 cells has also been found in
cerebrospinal fluid, neuro-Behc¸et’s disease, and skin lesions. Furthermore, the
analysis of transcription factor ratios revealed an increase in the RORC/FOXP3 and
TBX21/GATA3 ratios in Behc¸et’s patients with neurological manifestations,
indicating plasticity between Th1, Th17, and Treg cells during inflammation
(Hamzaoui et al. 2011; Pineton de Chambrun et al. 2012; Shimizu et al. 2012). A
high proportion of cytotoxic CD8?CD56?NKT, CD8?CD56?T, and cdT cells has
been reported in intraocular infiltration and skin lesions of Behc¸et’s patients
(Hamzaoui et al. 2012; Shimizu et al. 2012). An increased level of Th2 cytokines
has been assessed in patients with systemic complications (Kuchroo et al. 2012;
Pineton de Chambrun et al. 2012).
In addition, susceptibility seems to be associated with HLA-B51, particularly in
close family members (Pirim et al. 2004; Remmers et al. 2010; Kapsimali et al.
2010). Association of HLA-B51 has been recognized as the strongest genetic
susceptibility factor discovered so far, even though the pathogenic role of HLA-B51
has yet to be clarified, and available data suggest that there is possibly no single
mechanism associated with HLA-B51. Furthermore, there is no evidence supporting
the use of HLA-B51 as a diagnostic or prognostic marker for Behc¸et’s disease (Gul
and Ohno 2012).
Nevertheless, various host genetic factors, apart from HLA, have been
demonstrated to modulate susceptibility and the severity of organ and tissue
lesions, such as single nucleotide polymorphisms (SNPs) of Th1, Th2, and Th17
(Gregersen and Olsson 2009; Remmers et al. 2010; Cho and Gregersen 2011;
Pineton de Chambrun et al. 2012; Zhou et al. 2012). Recent genome-wide studies
have demonstrated associations of Th1, Th2, and Th17 SNPs with Behc¸et’s disease
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and its systemic manifestations, although other genetic studies have reported
contrasting data (Gregersen and Olsson 2009; Remmers et al. 2010; Cho and
Gregersen 2011; Pineton de Chambrun et al. 2012; Zhou et al. 2012).
Based on these observations, we typed Interleukin (IL)-12Bp40 (?1188A?C),
IL-18 (-137G?C), IL-4RA (?1902A?G), IL-13 (-1055C?T), and IL-10
(-1082G?A, -819C?T) genetic variants in a group of Sicilian patients and age-
and gender-matched controls.
Materials and Methods
Patients and Controls
Blood samples, collected in ethylenediamine tetra-acetate sterile tubes, were
obtained from 39 Sicilian patients affected by Behc¸et’s disease. They were enrolled
at the time of their admission to the Rheumatologic Unit of Palermo University
Hospital. All patients (ages 20–50 years; 13 men and 26 women) were diagnosed
according to the criteria prepared by the International Study Group for Behcet’s
Disease (1999; Mignogna et al. 2000). As expected (Pipitone et al. 2004), the most
frequent symptoms (Table 1) were oral aphthae and, with lesser frequency, genital
aphthae. A minority of patients suffer from ocular or cutaneous involvement or
arthritis. These clinical features were observed both as isolated manifestations or as
complex pictures.
An age- and gender-matched control group of 128 individuals was also included
in our study. They were in good health according to their clinical history and blood
tests (complete blood cell count, erythrocyte sedimentation rate, glucose, urea
nitrogen, creatinine, electrolytes, C reactive protein, liver function tests, iron, and
proteins). Furthermore, we selected a homogeneous population for ethnicity and
geographic area. Patients and controls belonged to the same ethnic group, since their
parents and grandparents were born in western Sicily.
Our study received approval from local ethics committees, and all participants
gave their informed consent. Data were encoded to ensure patient and control
protection. All measurements were performed without knowledge about the nature
of the materials.
Table 1 Frequency of clinical
features at disease onset in
patients with Behc¸et’s disease
Clinical feature Frequency
Oral aphthae 71.8
Genital aphthae 23.1
Cutaneous lesions 17.9
Erythema nodosum 10.2
Inflammatory ocular involvement 20.5
Anterior uveitis 12.8
Arthritis 15.4
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Genotyping of Th1 and Th2 Cytokine Gene SNPs
DNA from patient and control blood samples was prepared by proteinase K
digestion and salt extraction (Miller et al. 1988).
The ?1188A/C IL-12Bp40 SNP was genotyped in 35 patients and 128 controls,
using PCR-restriction fragment length polymorphism (PCR-RFLP) analysis
according to Huang et al. (2000). Using nested PCR, as described by Giedraitis
et al. (2001), we identified the -137G/C IL-18 SNP in 32 patients and 128 controls.
Through an amplification refractory mutational system (ARMS-PCR) procedure
(Cataldo et al. 2003), the ?1902A/G IL-4RA SNP was identified in 36 patients and
128 controls and the -1055C/T IL-13 SNP was genotyped in 37 patients and 128
controls. Procedures previously described by Lio et al. (2004) were used to
genotype the -1082G/A and -819C/T IL-10 SNPs in 39 patients and 128 controls.
In addition, patients and controls were genotyped for the HLA-B51 allele as
described by Pirim et al. (2004).
Statistical Analysis
Allele and genotype frequencies were evaluated by gene count. Data were tested for
goodness of fit between observed and expected genotype frequencies according to
Hardy–Weinberg equilibrium, by a chi-square test. Significant differences in
frequencies among groups were calculated using the chi-square test and appropriate
tables. Odds ratios with 95% confidence intervals and their significance were
calculated.
Results
In the genotype distributions and allele frequencies, very significant differences
were observed between patients with Behc¸et’s disease and controls for the SNPs
?1188A/C IL-12Bp40, ?1902A/G IL-4RA, and -1055C/T IL-13 (Table 2). In
particular, the frequencies of the IL-12Bp40 ?1188C allele and related C-positive
genotypes (?1188C/*) were higher in patients than in controls. In addition, the
frequency of the ?1902G/* IL-4RA genotype was higher in patients than in
controls. Accordingly, overexpression of the ?1902G allele was found in patients
with respect to controls. We also observed in patients a very significant distribution
of -1055T/* genotypes with respect to the controls, and an overexpression of the
-1055T allele was found in patients.
In contrast, no statistically significant differences in genotype distributions or
allele frequencies were observed for the -137G/C IL-18, -1082G/A, and -819C/T
IL-10 SNPs (Table 2). In addition, no statistically significant differences were
observed stratifying our results for the presence of the HLA-B51 allele between
patients and controls (data not shown). We also evaluated the frequencies of the
combined genotypes. Considering all possible combinations, significant differences
were observed for only two combinations (Table 3). We found significantly higher
frequencies of the IL-12Bp40 ?1188C/* IL-18-137GG combination (43 vs. 18%,
970 Biochem Genet (2013) 51:967–975
123
p = 0.002) and the IL-4RA ?1902G/* IL-13 -1055T/* IL-10 -1082GG combi-
nation (23 vs. 9%, p = 0.03) in patients.
Discussion
Genetic predisposition and immune deregulation are considered crucial factors for
Behc¸et’s pathogenesis, although cellular and molecular mechanisms remain unclear.
In particular, the exact role of the cytokine network in the pathophysiology of the
disease needs further elucidation (Kapsimali et al. 2010). Recent findings of in vivo
or in vitro studies show the promotion of different Th (Th1, Th2, and Th17)
Table 2 Genotype distributions and allele frequencies of six SNPs in Behc¸et’s disease patients and
matched controls
Gene Genotype and allele Behc¸et’s patients Matched controls p OR (95% CI)
IL-12Bp40 N = 35 N = 128
?1188AA 0.38 0.68 0.0005 2.92 (1.6–5.2)
p = 0.0005?1188C/* 0.62 0.32
?1188A 0.63 0.83 0.0002
?1188C 0.37 0.17
IL-18 N = 32 N = 128
-137GG 0.60 0.52 NS
-137C/* 0.40 0.48
-137G 0.75 0.73
-137C 0.25 0.27
IL-4RA N = 36 N = 128
?1902AA 0.20 0.63 0.000005 2.6 (1.5–4.6)
p = 0.001?1902G/* 0.80 0.37
?1902A 0.60 0.80
?1902G 0.40 0.20 0.0005
IL-13 N = 37 N = 128
-1055CC 0.16 0.68 1.6 9 e-7 3.57 (2–6.2)
p \ 0.0001-1055T/* 0.84 0.32
-1055C 0.58 0.83
-1055T 0.42 0.17 0.000005
IL-10 N = 39 N = 128
-1082GG 0.44 0.37 NS
-1082A/* 0.56 0.63
-1082G 0.60 0.61 NS
-1082AG 0.40 0.39
-819C/* 0.80 0.90 NS
-819TT 0.20 0.10
-819C 0.63 0.66
-819T 0.37 0.34 NS
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responses in the complex pathophysiology and its organ and tissue lesions
(Kapsimali et al. 2010; Kuchroo et al. 2012; Pineton de Chambrun et al. 2012; Zhou
et al. 2012). In addition, several associations have been demonstrated of the Th1,
Th2, and Th17 genetic variants with Behc¸et’s disease risk and severity of ocular,
pulmonary, vascular, neurological, and intestinal lesions, as extensively and
recently reported by Zhou et al. (2012).
In the present study, we investigated some genetic variants of Th1/Th2 cytokine
genes in Sicilian Behc¸et’s patients and age- and gender-matched controls. In
particular, six functional SNPs were investigated in the promoter or exon regions of
the IL-12Bp40, IL-18, IL-13, IL-4RA, and IL-10 genes, which are able to modify
cytokine production or Th1/Th2 polarization. SNPs that affect cytokine expression
represent disease modifiers and influence the severity or progression of immune-
mediated and chronic inflammatory diseases. Cytokine SNPs have been associated
with common diseases, including cardiovascular diseases, cancer, neurodegenera-
tive diseases, allergies, asthma, and autoimmune diseases, such as Behc¸et’s disease
(Ollier 2004; Hollegaard and Bidwell 2006; Dilek et al. 2009; Pineton de Chambrun
et al. 2012). These are all multigenic and multifactorial diseases, involving
interactions between genetic, physiological, and environmental factors. Thus, the
identification of possible genetic risk factors for Behc¸et’s disease might improve
diagnostic accuracy, as well as permit disease stratification for risk assessment and
treatment selection (McCarthy et al. 2008; Plomin et al. 2009; Gregersen and Olsson
2009; Remmers et al. 2010; Cho and Gregersen 2011). Individually, however, most
disease-associated alleles carry very modest degrees of risk.
Our study results demonstrate associations with ?1188A/C IL-12Bp40, ?1902A/
G IL-4RA, and -1055C/T IL-13 SNPs, but the analysis of odds ratios for single SNPs
demonstrates a modest contribution of each single variant to Behc¸et’s disease
susceptibility. On the other hand, when the contemporaneous presence of at least three
genetic variants was evaluated according to the Th1 or Th2 profiles, our data
demonstrated significant differences between patients and controls with respect to the
higher odds ratios for the IL-12Bp40 ?1188C/* IL-18-137GG and IL-4RA ?1902G/*
IL-13 -1055T/* IL-10 -1082GG genotype combinations. Thus, our results suggest
an involvement of both Th1 and Th2 cytokine pathways in the development of
Behc¸et’s disease. Furthermore, they lead to the suggestion that the disease risk
increases in individuals carrying a combination of the genetic variants of IL-12Bp40,
IL-18, IL-4RA, IL-13, and IL-10. Our data are partially in agreement with those
obtained in a large genome-wide association study of Behc¸et’s patients from different
population backgrounds, demonstrating that variants in the IL10 and IL23R–IL12RB2
regions are associated with Behc¸et’s disease risk (Remmers et al. 2010).
In this view, we can hypothesize that various cytokine pathways are involved in the
pathogenesis of the disease, including the emerging role of the IL-23/IL-17 axis (Leng
et al. 2010; Hamzaoui 2011; Kuchroo et al. 2012). These genetically influenced
cytokine profiles might modulate the induction of different effector T CD4? cell
subsets involved in inflammation, tissue injury, and autoantibody production, driving
the different clinical profiles that characterize Behc¸et’s disease. The complex interplay
between Th1, Th17, Th2, and Treg cell lineages and their involvement in autoimmune
diseases such as Behc¸et’s suggests that it may be possible to develop preventive
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measures using specific inhibitors, such as monoclonal antibodies, against these
cytokines and their receptors. On the other hand, promising data propose an elegant
mechanism based on the use of cytokine inhibitors (i.e., monoclonal antibodies for
TGF-b and its receptors) for regulating the pathological potential of these cytokines,
particularly the cytokines of the emerging T effector subset of CD4? cells, Th17 cells.
This mechanism derives from the discovery that Th17 cells differ from Th1 and Th2
cells. Th1 and Th2 cells have been thought to represent terminal products of their
respective developmental programs. Recent studies suggest that Th17 cells are less
rigid. In addition to early developmental links to induced Tregs, reflecting the shared
requirement for TGF-b, it is now apparent that there is substantial plasticity late in the
Th17 program, which allows committed Th17 cells to transition from effectors that
produce predominantly IL-17A and IL-17F to effectors that produce predominantly
IFNc. In this setting, a fine balance between RORct and Foxp3 may be critical for
immune homeostasis. This promises new insights into strategies for balancing
inflammation and Th responses involved in the pathogenesis of several vascular
inflammatory pathologies and autoimmune diseases, such as Behc¸et’s disease, and
raises new questions regarding the stability of epigenetic modifications that
accompany induction of cytokine gene expression during T cell lineage development
(Lee et al. 2009). In light of these observations, a future objective of our studies will be
to investigate genetic variants of Th17 and Treg cytokine genes in a very large sample.
A limitation of our present study is the small sample size, which may restrict and
influence its statistical power. Nevertheless, we have studied a very homogeneous
patient population born in western Sicily and clinically followed in a single center.
Thus, even if larger cohort studies are necessary in order to definitively assess the true
associations of the IL-12Bp40, IL-4RA, and IL-13 alleles with Behc¸et’s disease, our
data might trigger innovative therapeutic approaches based on modulation of more
components of the cytokine pathways with different possibilities for immune response
modulation.
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